GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (NAS:GNFT) » Definitions » Debt-to-EBITDA

Genfit (Genfit) Debt-to-EBITDA : N/A (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Genfit Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genfit's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.64 Mil. Genfit's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $67.89 Mil. Genfit's annualized EBITDA for the quarter that ended in Dec. 2023 was $0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genfit's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of Genfit was 0.96. The lowest was -4.28. And the median was -2.34.

GNFT's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Genfit Debt-to-EBITDA Historical Data

The historical data trend for Genfit's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Debt-to-EBITDA Chart

Genfit Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.60 -2.15 0.96 -4.28 -3.16

Genfit Quarterly Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Genfit's Debt-to-EBITDA

For the Biotechnology subindustry, Genfit's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genfit's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genfit's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genfit's Debt-to-EBITDA falls into.



Genfit Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genfit's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.643 + 67.888) / -24.249
=-3.16

Genfit's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.643 + 67.888) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Genfit  (NAS:GNFT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genfit Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genfit's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genfit (Genfit) Business Description

Traded in Other Exchanges
Address
Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.